Global Folate Deficiency Anemia Drug Market: Focus on Collaborative Activities and Research & Development

Global Folate Deficiency Anemia Drug Market

Folate deficiency anemia drugs are the pharmaceuticals developed for the treatment of folic acid deficiency in patients which subsequently results in causing folate deficiency anemia. It is caused due to the lack of folic acid presence in the blood of patients. Patients suffer from lack of formulation of blood cells and the enhanced size of blood cells that are produced by the body. The drugs developed for the treatment of this condition are generally nutritional supplements that can provide the lack of folic acid and other nutritional content that is missing from the body.

Access Full Report at https://www.databridgemarketresearch.com/reports/global-folate-deficiency-anemia-drug-market

Folate deficiency anemia drug market is growing due to prevalence of inflammatory bowel disease worldwide, increase cases of kidney disorders where dialysis is predominant treatment; the effects of these factors are mentioned below:

  • Prevalence of inflammatory bowel disease worldwide: Inflammatory bowel disease is generally caused with a lack of iron in the patient body causing a combination of iron deficiency anemia and chronic anemia. This combination is known to cause chronic inflammation of digestive system which subsequently causes patients to be more prone against diarrhea and abdominal pain. The combination of these disorders can be treated with the help of consuming various nutritional supplements that are missing from the diet of patients
  • Increase cases of kidney disorders where dialysis is predominant treatment: With the high levels of kidney disorders, patient’s bodies cannot properly process and extract the nutritional content required for the various bodily operations. Along with that, these patients are required to undergo dialysis which results in lowering the content of folic acid in patients, subsequently causing a higher prevalence of folate deficiency anemia at a higher level in the global population

Some of the key market developments are as follows:

  •  In April 2019, Merck announced the launch of “Arcofolin L-Methylfolate”, providing supplementation for natural folate that can be lost during dietary consumptions. It is an active form of folic acid which is easier for the patient’s body to metabolize, and hence does not require special absorption requirements
  • In January 2015, Helsinn Group and Pharmacosmos A/S announced that they had entered into an agreement for the commercialization of Monofer in the United States region. It is an intravenous iron replacement therapy designed for the correction of iron deficiency anemia. Helsinn will provide production, supply payments to Pharmacosmos A/S to Monofer, with certain milestone payments amounting to USD 130 million on meeting certain demands

The market is segmented on the basis of type as dietary folate deficiency anemia, drug-induce folate deficiency anemia, unspecified folate deficiency anemia, others; treatment type is categorized into medication, dietary supplements; drug type as vitamin B12 injections, iron deficiency replacement drugs; route of administration as oral, injectable; end-users as hospitals, homecare, specialty clinics, others.

“According to Data Bridge Market Research, global folate deficiency anemia drug market is expected to be growing with a substantial CAGR during the forecast period of 2019 to 2026”

Some of the major players operating in market are GlaxoSmithKline plc, Eli Lilly and Company, Merck KGaA, bluebird bio, Inc, Biocon, GlycoMimetics, Regen BioPharma Inc, Bayer AG, Acceleron Pharma, Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co., Inc, Novartis AG, Teva Pharmaceutical Industries Ltd., AMAG Pharmaceuticals, Akebia Therapeutics, Vifor Pharma Management Ltd, Omeros Corporation, PHARMACOSMOS A/S, Helsinn Healthcare SA, and many others.

Due to the lack of major market players that have a global presence in the industry and dealing in the treatment of folate deficiency anemia drug, many of the manufacturers have initiated strategic alliances with other market players having presence in the geographical regions different from theirs. They have also been focusing on better development practices and research activities in collaboration with different market players, which combines different technologies to provide an enhanced platform.